APA (7th ed.) Citation

Henney, A. E., Riley, D. R., O'Connor, B., Hydes, T. J., Anson, M., Zhao, S. S., . . . Cuthbertson, D. J. (2024). Denosumab, for osteoporosis, reduces the incidence of type 2 diabetes, risk of foot ulceration and all‐cause mortality in adults, compared with bisphosphonates: An analysis of real‐world, cohort data, with a systematic review and meta‐analysis. Wiley. https://doi.org/10.1111/dom.15708

Chicago Style (17th ed.) Citation

Henney, Alex E., David R. Riley, Ben O'Connor, Theresa J. Hydes, Matthew Anson, Sizheng Steven Zhao, Uazman Alam, and Daniel J. Cuthbertson. Denosumab, for Osteoporosis, Reduces the Incidence of Type 2 Diabetes, Risk of Foot Ulceration and All‐cause Mortality in Adults, Compared with Bisphosphonates: An Analysis of Real‐world, Cohort Data, with a Systematic Review and Meta‐analysis. Wiley, 2024. https://doi.org/10.1111/dom.15708.

MLA (9th ed.) Citation

Henney, Alex E., et al. Denosumab, for Osteoporosis, Reduces the Incidence of Type 2 Diabetes, Risk of Foot Ulceration and All‐cause Mortality in Adults, Compared with Bisphosphonates: An Analysis of Real‐world, Cohort Data, with a Systematic Review and Meta‐analysis. Wiley, 2024. https://doi.org/10.1111/dom.15708.